PMID- 29705628 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20220409 IS - 1877-783X (Electronic) IS - 1877-7821 (Linking) VI - 54 DP - 2018 Jun TI - Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK. PG - 104-111 LID - S1877-7821(18)30115-2 [pii] LID - 10.1016/j.canep.2018.04.008 [doi] AB - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have been shown to have higher incidences of liver, pancreatic, and colorectal cancer compared to non-diabetic individuals. Current evidence is conflicting for other gastrointestinal (GI) cancers. Therefore, we aimed to determine incidence rates (IRs) of all GI cancers in patients with and without T2DM. METHODS: A cohort study was performed using the UK Clinical Practice Research Datalink (1988-2012). A cohort of antidiabetic drug users was matched at baseline to a non-diabetic cohort, by age, sex, and practice. Crude IRs and 95% confidence intervals (95% CI) of GI cancers per 100,000 person-years were calculated stratified by age, sex, and calendar year. RESULTS: 333,438 T2DM and 333,438 non-diabetic individuals were analyzed. IRs of liver (IR 26, 95% CI 24-28 vs. 8.9, 95% CI 7.7-10), pancreatic (IR 65, 95% CI 62-69 vs. 31, 95% CI 28-34), and colon cancer (IR 119, 95% CI 114-124 vs. 109, 95% CI 104-114) were significantly higher in the diabetic compared to the non-diabetic cohort, whereas the IR of oesophageal cancer was significantly lower (IR 41, 95% CI 39-44 vs. 47, 95% CI 44-51). Sex-specific IRs of colon cancer remained significantly higher in men with T2DM, and IRs of esophageal cancer remained significantly lower in women with T2DM. CONCLUSION: In this study, T2DM patients were shown to have higher crude IRs of liver, pancreatic and colon cancer, but not of gastric, biliary, and rectal cancer. Moreover, the lower observed IRs of oesophageal cancer in diabetic patients warrants further investigation. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - de Jong, Roy G P J AU - de Jong RGPJ AD - Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands. Electronic address: roy.dejong@maastrichtuniversity.nl. FAU - Peeters, Paul J H L AU - Peeters PJHL AD - Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands. FAU - Burden, Andrea M AU - Burden AM AD - Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - de Bruin, Marie L AU - de Bruin ML AD - Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands. FAU - Haak, Harm R AU - Haak HR AD - Department of Internal Medicine, Maxima Medical Centre Eindhoven, Eindhoven, Netherlands; Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands; Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - Masclee, Ad A M AU - Masclee AAM AD - Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands; NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - de Vries, Frank AU - de Vries F AD - Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre+, Maastricht, The Netherlands; MRC Life-course Epidemiology Unit, University of Southampton, Southampton, United Kingdom. Electronic address: f.devries@uu.nl. FAU - Janssen-Heijnen, Maryska L G AU - Janssen-Heijnen MLG AD - GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180516 PL - Netherlands TA - Cancer Epidemiol JT - Cancer epidemiology JID - 101508793 RN - 0 (Hypoglycemic Agents) SB - IM MH - Aged MH - Cohort Studies MH - Colorectal Neoplasms/*epidemiology MH - Diabetes Mellitus, Type 2/*epidemiology MH - Esophageal Neoplasms/*epidemiology MH - Female MH - Gastrointestinal Neoplasms/*epidemiology MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - Incidence MH - Male MH - Middle Aged MH - Risk Factors MH - United Kingdom/epidemiology OTO - NOTNLM OT - Epidemiology OT - Gastrointestinal cancer OT - Incidence OT - Incidence rates OT - Type 2 diabetes mellitus EDAT- 2018/05/01 06:00 MHDA- 2019/04/04 06:00 CRDT- 2018/04/30 06:00 PHST- 2017/12/26 00:00 [received] PHST- 2018/04/11 00:00 [accepted] PHST- 2018/05/01 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2018/04/30 06:00 [entrez] AID - S1877-7821(18)30115-2 [pii] AID - 10.1016/j.canep.2018.04.008 [doi] PST - ppublish SO - Cancer Epidemiol. 2018 Jun;54:104-111. doi: 10.1016/j.canep.2018.04.008. Epub 2018 May 16.